Opus Genetics (IRD) to Post Earnings on Wednesday

Opus Genetics (NASDAQ:IRD) is expected to announce its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $2.6280 million for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 12:30 PM ET.

Opus Genetics (NASDAQ:IRD) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.59). The firm had revenue of $2.16 million for the quarter, compared to the consensus estimate of $2.93 million. Opus Genetics had a negative net margin of 892.36% and a negative return on equity of 338.88%. On average, analysts expect Opus Genetics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Opus Genetics Trading Up 1.9%

Opus Genetics stock opened at $3.71 on Wednesday. The firm has a 50-day moving average of $3.84 and a 200-day moving average of $4.09. The firm has a market cap of $306.32 million, a P/E ratio of -2.79 and a beta of 0.59. Opus Genetics has a 1-year low of $1.04 and a 1-year high of $5.81.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on IRD shares. Zacks Research downgraded Opus Genetics from a “hold” rating to a “strong sell” rating in a report on Monday, July 13th. HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of Opus Genetics in a report on Wednesday, June 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Opus Genetics in a research report on Friday, July 17th. Leerink Partners assumed coverage on Opus Genetics in a research note on Thursday, May 21st. They set an “outperform” rating and a $10.00 target price on the stock. Finally, TD Cowen assumed coverage on Opus Genetics in a report on Wednesday, July 29th. They set a “buy” rating for the company. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.77.

Insider Activity

In other Opus Genetics news, Director Fighting Blindness Foundation sold 1,700,000 shares of Opus Genetics stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $4.35, for a total transaction of $7,395,000.00. Following the sale, the director directly owned 3,792,171 shares of the company’s stock, valued at approximately $16,495,943.85. The trade was a 30.95% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO George Magrath sold 9,475 shares of Opus Genetics stock in a transaction that occurred on Thursday, July 23rd. The shares were sold at an average price of $2.95, for a total value of $27,951.25. Following the sale, the chief executive officer directly owned 1,731,869 shares in the company, valued at approximately $5,109,013.55. The trade was a 0.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 1,729,331 shares of company stock valued at $7,481,629 over the last 90 days. 11.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Opus Genetics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Virtu Financial LLC purchased a new stake in shares of Opus Genetics in the 4th quarter worth about $34,000. Occudo Quantitative Strategies LP bought a new stake in Opus Genetics during the fourth quarter worth about $25,000. Opaleye Management Inc. grew its holdings in Opus Genetics by 1.8% in the fourth quarter. Opaleye Management Inc. now owns 1,120,000 shares of the company’s stock worth $2,251,000 after purchasing an additional 20,000 shares during the period. Millennium Management LLC bought a new position in shares of Opus Genetics during the fourth quarter valued at approximately $4,025,000. Finally, Balyasny Asset Management L.P. bought a new position in shares of Opus Genetics during the fourth quarter valued at approximately $5,463,000. Hedge funds and other institutional investors own 14.97% of the company’s stock.

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.